Stifel Maintains Buy on Nurix Therapeutics, Raises Price Target to $40
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Stifel analyst Stephen Willey maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $34 to $40.
Stifel analyst Stephen Willey maintains Nurix Therapeutics (NASDAQ:NRIX) with a Buy and raises the price target from $34 to $40.